Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to White Bagging.
Duration: August 1, 2020
to
present
General Issues: Medicare/Medicaid , Health Issues
Spending: about $1,160,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: U.S. Senate, House of Representatives, Medicare Payment Advisory Commission (MedPAC), Centers For Medicare and Medicaid Services (CMS)
Affiliated organizations: IVX Health; Altus Biologics; Healix; McKesson
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
John McManus Staff Director, W&M Health Subcommittee; LA, Rep. Bill Thomas.
Staff Director, W&M Health Subcommittee. LA, Rep. Bill Thomas.
ALANNA TEMME LD, Rep. Jon Porter.
Lawren Geer n/a
Alex Whalen n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on April 22.
Original Filing: 301575905.xml
Lobbying Issues
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act.
Issues related to White Bagging.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on Jan. 20.
Original Filing: 301534011.xml
Lobbying Issues
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to down coding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
Advocating for access to biosimilars.
HR 5391, S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act.
S. 652/HR 2630, Safe Step Act
S. 1375/HR 830, HELP Copays Act
Issues related to White Bagging.
Access to Alzheimer's Disease therapies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to PPBM transparency, including, H.R.5378 - Lower Costs, More Transparency Act
Agencies Lobbied
U.S. Senate
3rd Quarter, 2023
In Q3, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on Oct. 20, 2023.
Original Filing: 301516564.xml
Lobbying Issues
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act, S.2973 - Modernizing and Ensuring PBM Accountability Act, H.R.2880 - Protecting Patients Against PBM Abuses Act.
Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
Issues related to MACRA reform.
Advocating for access to biosimilars.
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 -Inflation Reduction Act of 2022; H.R.8800 - Supporting Medicare Providers Act of 2022; HR 2474, the Strengthening Medicare for Patients and Providers Act; Access and appropriate reimbursement for Part B drugs in clinic setting; support for site neutral payment policies; access to Alzheimer's Disease therapies; Medicare Administrative Contractor coding issues (non-legislative); HR 5391, Protecting Patient Access to Cancer and Complex Therapies Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 2691, the Transparent PRICE Act; S 652/HR 2630, Safe Step Act; S 1375/HR 830, HELP Copays Act; H.R. 2679, the PBM Accountability Act; S. 1339, Pharmacy Benefit Manager Reform Act; H.R. 3284, the Providers and Payers COMPETE Act; H.R. 3237, requiring each off-campus outpatient department of a provider to include a unique identifier; H.R. 3285, the Fairness for Patient Medications Act; H.R. 3262, to increase transparency of certain health-related ownership information; S. 1214, the RARE Act; The Lower Costs, More Transparency Act; The Stop Drug Shortages Act; H.R. 4822; Health Care Price Transparency Act of 2023; The Patient Act; Improving Seniors Timely Access to Care Act; The Cutting Copays Act; The Modernizing and Ensuring PBM Accountability Act; The Transparency in Billing Act.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2023
In Q2, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on July 20, 2023.
Original Filing: 301490331.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting
Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022.
Issues related to Pharmacy Benefit Manager reform included in S. 1339 - Pharmacy Benefit Manager Reform Act, H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023, S.127 PBM Transparency Act of 2023, H.R. 4507 -Transparency in Coverage Act of 2023, S. 1967 - PBM Act.
Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023.
Issues related to MACRA reform.
HR 2474, the Strengthening Medicare for Patients and Providers Act.
Advocating for access to biosimilars.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies to remove barriers to physician prescribing decisions including in H.R.2630/S.652 - Safe Step Act.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on April 20, 2023.
Original Filing: 301466822.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies to remove barriers to physician prescribing decisions including in H.R.2630/S.652 - Safe Step Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on Jan. 20, 2023.
Original Filing: 301438448.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies.
Issues related to payments cuts to the Medicare Physician Fee Schedule including in H.R.8800 - Supporting Medicare Providers Act of 2022 and Sec. 4112 of H.R. 2617 - Consolidated Appropriations Act of 2023 (P.L. No: 117-328)/
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies to remove barriers to physician prescribing decisions including in H.R. 2163/S.464 - Safe Step Act of 2021.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on Oct. 20, 2022.
Original Filing: 301415226.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Title I-Subtitle B of P.L. 117-169/H.R. 5376 - Inflation Reduction Act of 2022.
Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies.
Issues related to physician payments included in H.R.8800 - Supporting Medicare Providers Act of 2022.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies to remove barriers to physician prescribing decisions including in H.R. 2163/S.464 - Safe Step Act of 2021.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on July 20, 2022.
Original Filing: 301390284.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Subtitle J of H.R. 5376 - Build Back Better Act and Senate reconciliation bill.
Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policies to remove barriers to physician prescribing decisions including in H.R. 2163/S.464 - Safe Step Act of 2021.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on April 20, 2022.
Original Filing: 301365246.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs).
Support for site neutrality policies.
Access to Alzheimer's Disease therapies.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on Jan. 20, 2022.
Original Filing: 301335974.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Subtitle J of H.R. 5376 - Build Back Better Act.
Support of reinstating step therapy prohibition in Medicare Advantage Plans for Part B drugs.
Issues related to provider payment cuts addressed in S. 610 - Protecting Medicare and American Farmers from Sequester Cuts Act and H.R. 6143 - Supporting Health Care Providers During the COVID-19 Pandemic Act.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on Oct. 20, 2021.
Original Filing: 301311250.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting and provisions included in Subtitle J - Drug Pricing of H.R. 5376 - Build Back Better Act.
Support of reinstating step therapy prohibition in Medicare Advantage Plans for Part B drugs.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on July 20, 2021.
Original Filing: 301284473.xml
Lobbying Issues
Access and appropriate reimbursement of Part B drugs in clinic setting.
Support of reinstating step therapy prohibition in Medicare Advantage Plans for Part B drugs.
Extension to Medicare sequester delay in S. 748 - A Bill to Provide for an Extension of the Temporary Suspension of Medicare Sequestration During the COVID-19 Public Health Emergency, H.R. 1868 - To Prevent Across-The-Board Direct Spending Cuts, and For Other Purposes, H.R. 315 - Medicare Sequester COVID Moratorium Act and H.R.1999 - To delay and offset the sequester under the Statutory Pay-As-You-Go Act of 2010 as a result of the enactment of the American Rescue Plan Act of 2021, and for other purposes.
Agencies Lobbied
U.S. Senate
1st Quarter, 2021
In Q1, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $80,000. The report was filed on April 20, 2021.
Original Filing: 301264543.xml
Lobbying Issues
Access and appropriate reimbursement to Part B drugs.
Extension to Medicare sequester delay in S. 748 - A Bill to Provide for an Extension of the Temporary Suspension of Medicare Sequestration During the COVID-19 Public Health Emergency, H.R. 1868 - To Prevent Across-The-Board Direct Spending Cuts, and For Other Purposes, H.R. 315 - Medicare Sequester COVID Moratorium Act and H.R.1999 - To delay and offset the sequester under the Statutory Pay-As-You-Go Act of 2010 as a result of the enactment of the American Rescue Plan Act of 2021, and for other purposes.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $60,000. The report was filed on Jan. 19, 2021.
Original Filing: 301234776.xml
Lobbying Issues
Access to Part B drugs.
Most Favored Nation (MFN) Model, (CMS-5528-IFC).
Extension of Medicare sequester delay in Division N Sec. 102 of H.R. 133 The Consolidated Appropriations Act of 2020.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2020
In Q3, THE MCMANUS GROUP lobbied for Infusion Providers Alliance , earning $60,000. The report was filed on Oct. 14, 2020.
Original Filing: 301209664.xml
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...